Table 3.
Transmission blocking activity: dose dependent efficacy of NeemAzal® (NA) on Plasmodium falciparum oocyst prevalence and density
| Blood sample number | Gametocytes per μL blood | Treatment and concentration | Prevalence of infected mosquitoes% (infected/total examined) | Mean number of oocysts/mosquito (CI 95 ) |
|---|---|---|---|---|
| 11 |
400 |
control |
64 (09/14) |
51.36 (12.83-89.88) |
| NA 70 ppm |
0 (0/25) |
0.00 |
||
| 12 |
1760 |
control |
75 (12/16) |
94.38 (38.29-150.46) |
| NA 70 ppm |
0 (00/25) |
0.00 |
||
| 17 |
112 |
control |
80 (12/15) |
4.53 (2.69-6.38) |
| NA 60 ppm |
0 (0/31) |
0.00 |
||
| 16 |
184 |
control |
64 (29/45) |
4.58 (2.96-6.19) |
| NA 60 ppm |
0 (0/56) |
0.00 |
||
| 15 |
344 |
control |
90 (09/10) |
131.00 (49.69-212.31) |
| NA 60 ppm |
12 (03/25) |
0.36 (0.00-0.83) |
||
| 11 |
400 |
control |
68 (17/25) |
49.36 (22.92-75.80) |
| NA 60 ppm |
0 (0/25) |
0.00 |
||
| 12 |
1760 |
control |
75 (12/16) |
94.38 (38.29-150.46) |
| NA 60 ppm |
0 (0/25) |
0.00 |
||
| 17 |
112 |
control |
85 (11/13) |
3.92 (1.91-5.93) |
| NA 50 ppm |
23 (07/31) |
0.35 (0.05-0.66) |
||
| 16 |
184 |
control |
59 (24/41) |
2.68 (1.58-3.79) |
| NA 50 ppm |
0 (0/46) |
0.00 |
||
| 15 |
344 |
control |
92 (24/26) |
151.58 (97.31-205.84) |
| NA 50 ppm |
36 (15/42) |
2.29 (0.60-3.97) |
||
| 11 |
400 |
control |
82 (28/34) |
66.50 (44.04-88.96) |
| NA 50 ppm |
0 (0/23) |
0.00 |
||
| 6 |
528 |
control |
90 (54/60) |
42.85 (31.36-54.34) |
| NA 50 ppm |
18 (11/61) |
0.30 (0.10-0.49) |
||
| 17 |
112 |
control |
67 (18/27) |
6.56 (3.60-9.51) |
| NA 20 ppm |
52 (12/23) |
2.57 (0.86-4.27) |
||
| 16 |
184 |
control |
84 (38/45) |
4.42 (2.92-5.93) |
| NA 20 ppm |
41 (26/63) |
0.95 (0.56-1.34) |
||
| 15 |
344 |
control |
81 (29/36) |
92.69 (47.92-137.46) |
| NA 20 ppm |
60 (12/20) |
44.85 (7.90-81.80) |
||
| 6 |
528 |
control |
85 (44/52) |
32.90 (22.36-43.45) |
| NA 20 ppm | 88 (44/50) | 27.24 (19.12-35.36) |